PRESS RELEASE

Notification from Oasmia Pharmaceutical

Uppsala, May 16, 2018 --- Oasmia Pharmaceutical AB (publ) hereby notify that the Company, Arwidsro Investment and MGC Capital have agreed to extend the payment of the loan, which was communicated January 2nd until September 30th. The reason for the extension is to give the Company time to fulfil ongoing activities. All other terms apply unchanged for the loan.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

This information is such that Oasmia Pharmaceutical AB (publ) is obliged to disclose under the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 18.00 CET on 16 May 2018.